Alterity Therapeutics (ATHE) vs Nasus Pharma (NSRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alterity Therapeutics (ATHE) has outperformed Nasus Pharma (NSRX) over the past year, losing 56.7% versus a loss of 68.4%. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $26.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATHE | NSRX |
|---|---|---|
| Share price | $1.52 | $2.29 |
| Market cap | $29.02M | $26.82M |
| 1-day change | -8.16% | -10.20% |
| YTD return | -50.65% | -74.97% |
| 1-year return | -56.70% | -68.41% |
| 5-year return | -85.38% | — |
| EPS (TTM) | $-0.90 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.24B |
| Net income (latest FY) | — | $-5.86M |
| Operating margin | — | -0.40% |
| Net margin | — | -0.47% |
| 52-week high | $5.89 | $9.50 |
| 52-week low | $1.52 | $1.98 |
| Distance from 52-week high | -74.19% | -75.89% |
| Analyst consensus | none | buy |
| Avg. price target upside | +771.71% | +758.95% |
| Average volume | 89.63K | 16.80K |
| Shares outstanding | 19.09M | 11.71M |
| Employees | 11 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATHE has outperformed NSRX by 11.7 percentage points over the past year.
About Alterity Therapeutics
ATHE stock →Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ATHE vs NSRX FAQ
Which is bigger, Alterity Therapeutics or Nasus Pharma?
Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $26.82M for Nasus Pharma (NSRX).
Which stock has performed better over the past year, ATHE or NSRX?
ATHE returned -56.70% over the past 12 months, compared with -68.41% for NSRX (price return, excluding dividends). Past performance does not predict future results.
Are Alterity Therapeutics and Nasus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.